A Study to Investigate the Effect of Food on Oral LBH589 Absorption in Patients With Advanced Solid Tumors

Inclusion criteria: * Patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists * Age ≥ 18 years old * Patients must have adequate laboratory values * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 * Ability to swallow capsules or tablets Exclusion criteria: * Patients with active central nervous system (CNS) disease or brain metastases except those who have been previously treated and have been stable for at least 3 months. * Patients with a second primary malignancy that is currently clinically significant or requiring active intervention * Impaired heart function or clinically significant heart disease * Impairment of gastrointestinal (GI) function, or GI disease that may significantly alter the absorption of LBH589 * Ongoing diarrhea * Liver or renal disease with impaired hepatic or renal functions * Concomitant use of any anti-cancer therapy or certain drugs * Female patients who are pregnant or breast feeding * Patients not willing to use an effective method of birth control Other protocol-defined inclusion/exclusion criteria may apply